76
|
Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Ikeda S, Sato K, Sugisawa J, Matsumoto Y, Miyata S, Sakata Y, Shimokawa H. P4156Coexistence and prognostic impacts of epicardial and microvascular coronary dysfunctions in patients with chest pain and unobstructive coronary artery disease - Involvement of Rho-kinase activation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Although the importance of coronary functional abnormalities has been emerging, including epicardial coronary spasm (vasospastic angina, VSA) and coronary microvascular dysfunction (CMD), comprehensive evaluation of the abnormalities in the same population remains to be examined.
Purpose
We examined the significance of coronary functional abnormalities in a comprehensive manner for both epicardial and microvascular coronary arteries in patients with chest pain and unobstructive coronary artery disease (CAD) as well as their prognostic impacts.
Methods and results
We prospectively enrolled 187 consecutive patients with suspected angina and unobstructive coronary arteries (M/F 113/74, 63.2±12.3 [SD] yrs.). We performed acetylcholine (ACh) provocation tests for coronary spasm, followed by functional tests for coronary microvascular function, including coronary flow reserve (CFR) and index of microcirculation resistance (IMR) during hyperemic state induced by intravenous adenosine. Among the 187 patients, ACh test identified 128 patients with VSA (68%). There was no significant difference in age, sex, or prevalence of traditional coronary risk factors between the non-VSA and the VSA groups. The median IMR value was significantly higher in the VSA group than in the non-VSA group [17.5 (12.0, 25.3) vs. 14.7 (10.7, 17.8), P=0.02], whereas CFR values were comparable between the 2 groups [2.51 (1.72, 3.35) vs. 2.66 (1.85, 3.64), P=0.34]. During the median follow-up period of 893 days, major adverse cardiac events (MACE), including cardiac death, non-fatal myocardial infarction, and hospitalization due to unstable angina pectoris, occurred in 10 patients (5.3%). Multivariable analysis revealed that IMR correlated with the incidence of MACE [hazard ratio (HR) (95% confidence interval), 1.05 (1.02–1.09), P=0.002] and receiver-operating characteristics curve analysis identified IMR of 18.0 as the optimal cut-off value for the incidence of cardiac events. When we divided the patients into the following 4 groups according to the cut-off value of IMR (>18) and the presence or absence of VSA; G1, IMR <18 without VSA (n=45); G2, IMR ≥18 without VSA (n=14); G3, IMR <18 with VSA (n=67); and G4, IMR ≥18 with VSA (n=61), the Kaplan-Meier survival analysis showed a significantly worse prognosis in G4 compared with other 3 groups (HR [95% CI] 6.23 [1.21–118.46], P=0.002) (Figure 1). Importantly, intracoronary administration of fasudil, a Rho-kinase inhibitor, significantly ameliorated IMR in G4 (P<0.0001) (Figure 2A), and %changes in IMR in response to intracoronary fasudil were more evident in G4 compared with other 3 groups (P<0.0001) (Figure 2B).
Conclusions
These results provide the first evidence that in patients with chest pain and unobstructive CAD, epicardial coronary spasm and increased microvascular resistance are frequently coexisted with worse long-term prognosis, for which Rho-kinase activationmay be involved.
Collapse
|
77
|
Terui Y, Sugimura K, Ota H, Hiroshi T, Sato H, Nochioka K, Tatebe S, Miyata S, Sakata Y, Ishida T, Takase K, Shimokawa H. P3117Usefulness of cardiac magnetic resonance imaging for early detection of subclinical chemotherapy-related cardiac dysfunction in cancer patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Long-term prognosis of cancer patients has been improved along with the progress in chemotherapies. However, chemotherapy-related cardiac dysfunction (CTRCD) is emerging as a serious adverse effect as it worsens patients' outcome and quality of life. Thus, early detection of subclinical CTRCD is an important emerging issue in the management of cancer patients. Cardiac magnetic resonance (CMR) utilizes parametric mapping approach and strain analysis to provide detailed information about cardiac tissue and diastolic cardiac function.
Purpose
We examined whether the novel CMR imaging techniques are useful for early detection of CTRCD.
Methods and results
We performed both retrospective and prospective studies. (1) Retrospective study: We retrospectively enrolled 52 cancer patients (mean age 55.6±13 yrs., M/F=14/38) who had been treated with anthracyclines. We examined the usefulness of CMR for quantitative assessment of myocardial fibrosis caused by chemotherapies. We found that native T1 value was significantly prolonged in cancer patients compared with healthy controls (N=10) (1,279±56 vs. 1,240±34 msec, P=0.036). (2) Prospective study: A total of 99 consecutive female patients with breast cancer treated with chemotherapies were enrolled in this study from August 2017 to January 2019. To evaluate CTRCD in those patients, we performed CMR (at baseline and/or 6 months) and biomarkers analysis for cardiac troponin T (cTnT) and BNP at baseline and every 3 months during chemotherapies. In the 99 patients, 52 (mean age 53.0±12.7 yrs.) completed cardiac assessment at 6 months, and 6 (12%) developed CTRCD defined as a reduction in left ventricular ejection fraction (LVEF) >10% from baseline and below 53% without symptoms. In patients with CTRCD (CTRCD group, N=6), as compared with those without it (non-CTRCD group, N=46), native T1 value was significantly prolonged after chemotherapies (1,303±32 vs. 1,322±22 msec at 6 months, P=0.03). Plasma cTnT levels at 3 months were also significantly higher in the CTRCD group compared with the non-CTRCD group [0.022 (IQR 0.015–0.026) vs. 0.01 (0.006–0.014) ng/mL, P=0.024], whereas there was no difference in BNP values. In the 52 patients, 28 (mean age 56.3±12.3 yrs.) underwent CMR both before and 6 months after chemotherapies. In those patients, LVEF and global radial strain were significantly decreased at 6 months from baseline (LVEF, from 70.5±4.6 to 66.0±7.1%; global radial strain, from 70.0±22.5 to 61.1±22.6%, respectively, both P<0.05). In patients with elevated cTnT levels at 3 months, as compared with those without it, LVEF and extracellular volume fraction (ECV) at 6 months were significantly worse (LVEF, 59.0±6.0 vs. 62.7±2.6%, P=0.042; ECV, 32.3±2.9 vs. 30.2±2.3%, P=0.049, respectively).
Conclusions
These results indicate that novel CMR imaging techniques are useful for early detection of CTRCD among cancer patients treated with chemotherapies.
Collapse
|
78
|
Sakata Y, Hirai R, Tanizawa A, Kobuna K, Mori S. Heavy-ion Radiotherapy Rotating Gantry Calibration for Improving Patient Positioning Accuracy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
79
|
Yamaguchi T, Nakai M, Sumita Y, Nishimura K, Tazaki J, Kyuragi R, Kinoshita Y, Miyamoto T, Sakata Y, Nozato T, Ogino H. Endovascular Repair Versus Surgical Repair for Japanese Patients With Ruptured Thoracic and Abdominal Aortic Aneurysms: A Nationwide Study. J Vasc Surg 2019. [DOI: 10.1016/j.jvs.2019.06.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
80
|
Ueda A, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Dazai M, Kawahata S, Sasaki T, Sasaki Y, Kato S, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y. Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
81
|
Sakata Y, Yasui E, Mizukami M, Nagumo S. Cascade reaction including a formal [5 + 2] cycloaddition by use of alkyne-Co2(CO)6 complex. Tetrahedron Lett 2019. [DOI: 10.1016/j.tetlet.2019.01.045] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
82
|
Sakata S, Saeki S, Sakata Y, Kawamura K, Ichikado K, Inaba M, Ushijima S, Imamura K, Iyonaga K, Kumabe T, Fujita R, Kashiwabara K, Fujii S, Komatsu T, Sakamoto O, Okabayashi H, Saruwatari K, Tomita Y, Sakagami T. The impact of continuing ALK inhibitors beyond initial disease progression on clinical outcome in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter retrospective analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
83
|
Dazai M, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Nakano S, Ishiguro A, Tateyama M, Sato A, Kobayashi Y, Nakamura M, Okuda H, Takahashi Y, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y, Komatsu Y. HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
84
|
Ishiguro A, Yuki S, Nakano S, Kawamoto Y, Sawada K, Tsuji Y, Honda T, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
85
|
Yoshikawa A, Kawamoto Y, Yuki S, Nakano S, Sawada K, Muranaka T, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Saiki T, Ishiguro A, Saito R, Ehira N, Iwanaga I, Hatanaka K, Abe N, Sakamoto N, Sakata Y, Komatsu Y. HGCSG1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
86
|
Suzuki K, Yuki S, Nakano S, Kawamoto Y, Nakatsumi H, Hatanaka K, Ando T, Furukawa K, Ishiguro A, Ohta T, Eto K, Nakajima J, Nakamura M, Sogabe S, Kato K, Tateyama M, Kato S, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
87
|
Tsuji Y, Yuki S, Sawada K, Muranaka T, Kobayashi Y, Okuda H, Ogawa K, Minami S, Honda T, Dazai M, Kato T, Sasaki T, Shindo Y, Ota S, Sato A, Ueda A, Saitoh S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
88
|
Takeuchi M, Ichikawa W, Shitara K, Sunakawa Y, Oba K, Koizumi W, Sakata Y, Furukawa H, Takeuchi M, Fujii M. Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
89
|
Sato K, Takahashi J, Hao K, Sakata Y, Shimokawa H. P4618Temporal trends in emergency care and outcomes of geriatric patients with acute myocardial infarction in Japan - report from the miyagi AMI registry. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
90
|
Satoh K, Miyata S, Miura M, Ohtsuki T, Nochioka K, Sunamura S, Nogi M, Kurosawa R, Kikuchi N, Satoh T, Aoki T, Tatebe S, Sugimura K, Sakata Y, Shimokawa H. 1095Prognostic impacts of soluble form of basigin in patients with chronic heart failure - from a prospective large clinical trial with 1,147 patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
91
|
Aoyanagi H, Sakata Y, Nochioka K, Shiroto T, Oikawa T, Abe R, Kasahara S, Sato M, Takahashi J, Miyata S, Shimokawa H. P1801Impact of temporal changes in left ventricular ejection fraction in patients at risk for heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
92
|
Yonishi T, Minamiguchi J, Shiraki T, Matsuda Y, Ozu K, Kanda T, Masuda M, Miyoshi M, Mizote I, Mizuno Y, Hikoso S, Sakata Y. P6599Clinical impact of thyroxin levels on recurrence of atrial fibrillation after catheter ablation for patients without thyroid dysfunction: a multicenter study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
93
|
Ozu K, Minamiguchi H, Konishi S, Mizote I, Mizuno H, Hikoso S, Sakata Y. P6641Prediction of the distribution of local abnormal vetricular activities for ventricular tachycardia ablation with Tc-99m scintigram. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
94
|
Hao K, Takahashi J, Suda A, Sato K, Sugisawa J, Tsuchiya S, Sindo T, Ikeda S, Kikuchi Y, Matsumoto Y, Sakata Y, Shimokawa H. P4628Clinical significance of fractional flow reserve in patients with vasospastic angina and organic coronary stenosis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
95
|
Kimura Y, Nakano M, Sakata Y, Nochioka K, Hasebe Y, Abe R, Chiba T, Fukasawa K, Oikawa T, Kasahara S, Miki K, Sato M, Shiroto T, Miyata S, Shimokawa H. 4376Clinical impacts of wide ORS morphologies on deterioration of left ventricular ejection fraction and fatal arrhythmias in patients with relatively preserved left ventricular ejection function. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.4376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
96
|
Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Sato K, Sugisawa J, Matsumoto Y, Miyata S, Sakata Y, Shimokawa H. 1345Prognostic impacts of impaired coronary vasodilatation and enhanced coronary vasoconstricting responses in patients with angina and unobstructive coronary arteries. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
97
|
Kikuchi Y, Takahashi J, Sato K, Sugisawa J, Tsuchiya S, Suda A, Shindo T, Ikeda S, Hao K, Shiroto T, Matsumoto Y, Sakata Y, Shimokawa H. P793Usefulness and safety of fasudil, a selective Rho-kinase inhibitor, for PCI-related myocardial ischemia in interventional cardiology. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
98
|
Sakata Y, Yasui E, Takatori K, Suzuki Y, Mizukami M, Nagumo S. Syntheses of Polycyclic Tetrahydrofurans by Cascade Reactions Consisting of Five-Membered Ring Selective Prins Cyclization and Friedel–Crafts Cyclization. J Org Chem 2018; 83:9103-9118. [DOI: 10.1021/acs.joc.8b01195] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
99
|
Tominaga K, Sakata Y, Kusunoki H, Odaka T, Sakurai K, Kawamura O, Nagahara A, Takeuchi T, Fujikawa Y, Oshima T, Kato M, Furuta T, Murakami K, Chiba T, Miwa H, Kinoshita Y, Higuchi K, Kusano M, Iwakiri R, Fujimoto K, Tack JF, Arakawa T. Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: A randomized clinical trial (the DREAM study). Neurogastroenterol Motil 2018; 30:e13319. [PMID: 29498457 DOI: 10.1111/nmo.13319] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 01/26/2018] [Indexed: 02/05/2023]
Abstract
BACKGROUND Functional dyspepsia (FD), a heterogeneous disorder, involves multiple pathogenetic mechanisms. Developing treatments for FD has been challenging. We performed a randomized, placebo-controlled, double-blind clinical trial to determine the efficacy of rikkunshito, a Japanese herbal medicine, in FD patients. METHODS FD patients (n = 192) who met the Rome III criteria without Helicobacter pylori infection, predominant heartburn, and depression were enrolled at 56 hospitals in Japan. After 2 weeks of single-blind placebo treatment, 128 patients with continuous symptoms were randomly assigned to 8 weeks of rikkunshito (n = 64) or placebo (n = 61). The primary efficacy endpoint was global assessment of overall treatment efficacy (OTE). The secondary efficacy endpoints were improvements in upper gastrointestinal symptoms evaluated by the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM), the Global Overall Symptom scale (GOS), and the modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (m-FSSG), and psychological symptoms evaluated by the Hospital Anxiety and Depression Scale (HADS). KEY RESULTS Rikkunshito increased OTE compared to placebo at 8 weeks (P = .019). Rikkunshito improved upper gastrointestinal symptoms (PAGI-SYM, GOS, and m-FSSG) at 8 weeks, especially postprandial fullness/early satiety (P = .015 and P = .001) and bloating (P = .007 and P = .002) of the PAGI-SYM subscales at 4 weeks and 8 weeks. Improvement of HADS at 8 weeks (P = .027) correlated with those of PAGI-SYM (r = .302, P = .001), GOS (r = .186, P = .044), and m-FSSG (r = .462, P < .001), postprandial fullness/early satiety (r = .226, P = .014), dyspepsia (r = .215, P = .019), and PDS (r = .221, P = .016). CONCLUSION & INFERENCES Rikkunshito may be beneficial for FD patients to simultaneously treat gastrointestinal and psychological symptoms.
Collapse
|
100
|
Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|